An Irish pharmaceutical company is closing its Charlotte manufacturing plant, a move that will cost 390 local jobs.
The Charlotte Observer reports (http://bit.ly/1QY4G09) that Qualitest Pharmaceuticals, a subsidiary of Endo International, announced last week that it is closing the facility in Charlotte and reducing its Huntsville, Alabama, workforce to cut costs.
The company currently operates an 88,000-square-foot manufacturing plant in North Charlotte that produces tablets and capsules of generic medicines.
Qualitest: “Redefining Healthcare”
From its website:
“Qualitest provides affordable, high-quality generic pharmaceuticals. Featuring a portfolio of over 700 products, the company is now ranked in the top ten among all suppliers of generics, based on total prescriptions filled. Qualitest is an operating company of Endo International plc, a global specialty pharmaceutical company focused on improving patients’ lives while creating shareholder value.”
Endo Senior Director of Corporate Affairs Heather Zoumas Lubeski says the company will provide resources to “help employees manage through this transition.”
The restructuring and closure of the Charlotte plant is expected to save the company $60 million in 2017.
